Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Naotsugu Oyama"'
Autor:
Shunsuke Eguchi, Yohei Morita, Hironobu Mitani, Ayako Kanegasaki, Kosuke Iwasaki, Tsutomu Yoshikawa, Hiroshi Kitagawa, Naotsugu Oyama
Publikováno v:
Drugs - Real World Outcomes. 9:377-389
Repeated hospitalization is a predictor of outcomes in heart failure, indicating the presence of symptoms, a deteriorated condition at pre-admission, and worsened prognosis.The current database study aimed to understand the clinical and economic burd
Autor:
Nobutomo Matsui, Hiroki Murayama, Naoki Sato, Shigeto Yoshida, Takanori Ishii, Minako Funakubo, Roberto Abi Rached, Hironobu Mitani, Naotsugu Oyama
Publikováno v:
Journal of Cardiology. 76:342-349
Background Our objective was to characterize cases of hospitalized heart failure (HHF) focusing on in-hospital resource utilization (particularly furosemide doses) and worsening heart failure (WHF), and identify which factors are associated with the
Autor:
Hiroki Murayama, Naotsugu Oyama, Tomoko Taniguchi, Yosuke Ishida, Yohei Shinfuku, Takayoshi Sasajima
Publikováno v:
Expert Opinion on Drug Safety. 19:625-631
Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). However, the long-term safety, effectiveness, and clinical relationship with ...
Autor:
Erika Hayashi, Hollie Bailey, Hiroki Murayama, Sarah Cotton, Toshihisa Anzai, Hironobu Mitani, Rachel Studer, James C. Jackson, Naotsugu Oyama, Hiroshi Kitagawa
Publikováno v:
Geriatric nursing (New York, N.Y.). 42(2)
The aim of this cross-sectional survey was to characterize the role of and burden on caregivers of heart failure (HF) patients in Japan, since such data are limited at present. Data from 126 caregivers whose average age was 63.5 years were analyzed.
Autor:
Hiroki Murayama, Naotsugu Oyama, Yohei Shinfuku, Tomoko Hayashi, Isao Tsumiyama, Tomoko Taniguchi
Publikováno v:
Expert opinion on pharmacotherapy. 21(1)
Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with >750...
Autor:
Hiroki Murayama, Mitsutoshi Toda, Isao Tsumiyama, Naotsugu Oyama, Tomoko Taniguchi, Yohei Shinfuku, Yoshio Tanaka
Background: Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown. Research design and methods: This 2-year post-mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d18276745a2620703bdc4b16cf4eda1
Autor:
Ping Yen Liu, Naotsugu Oyama, Freddy Radtke, Thomas Gridley, Michael T. Chin, Michael I. Kotlikoff, Kyosuke Takeshita, Minoru Satoh, James K. Liao, Luke T. Krebs, Yuxin Li, Yasushi Mukai
Publikováno v:
Circulation. 119:2686-2692
Background— Notch1 regulates binary cell fate determination and is critical for angiogenesis and cardiovascular development. However, the pathophysiological role of Notch1 in the postnatal period is not known. We hypothesize that Notch1 signaling i
Publikováno v:
Vascular Disease Prevention. 3:285-289
Autor:
Kensuke Noma, Ping Yen Liu, Yukio Hiroi, Pilar Alcaide, Francis W. Luscinskas, Guijun Yan, James K. Liao, Naotsugu Oyama, Ryuji Okamoto, Yoshiyuki Rikitake, Daniela Ahl, Jianxin Sun, Naoki Sawada, Koichi Shimizu, Hong-Wei Wang
Publikováno v:
Journal of Clinical Investigation. 118:1632-1644
Although Rho-associated kinase (ROCK) activity has been implicated in cardiovascular diseases, the tissue- and isoform-specific roles of ROCKs in the vascular response to injury are not known. To address the role of ROCKs in this process, we generate
Publikováno v:
International Journal of Angiology. 16:27-30
A 49-year-old man with poorly controlled diabetes was admitted to Kushiro Rosai Hospital, Hokkaido, Japan after scalding both feet with boiling water. Because of poor healing, he was assessed for peripheral arterial disease. Angiography revealed tota